Jade Biosciences (NASDAQ:JBIO) Shares Gap Up – Here’s Why

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO) gapped up prior to trading on Thursday . The stock had previously closed at $22.55, but opened at $23.82. Jade Biosciences shares last traded at $21.5780, with a volume of 37,273 shares trading hands.

Wall Street Analyst Weigh In

Several analysts recently issued reports on JBIO shares. Jefferies Financial Group restated a “buy” rating and issued a $48.00 price target on shares of Jade Biosciences in a research note on Tuesday, August 11th. Piper Sandler set a $55.00 price target on Jade Biosciences in a report on Tuesday, June 2nd. UBS Group initiated coverage on Jade Biosciences in a research note on Monday, June 15th. They issued a “buy” rating and a $45.00 price target for the company. HC Wainwright boosted their price objective on Jade Biosciences from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, June 1st. Finally, Wedbush increased their price target on Jade Biosciences from $45.00 to $47.00 and gave the stock an “outperform” rating in a report on Monday, August 10th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Jade Biosciences presently has an average rating of “Moderate Buy” and an average target price of $51.75.

Jade Biosciences Price Performance

The stock has a market capitalization of $1.36 billion, a PE ratio of -11.11 and a beta of 1.49. The stock’s 50 day simple moving average is $20.93 and its two-hundred day simple moving average is $18.99.

Jade Biosciences (NASDAQ:JBIO) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities research analysts predict that Jade Biosciences, Inc. will post -2.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of JBIO. Legal & General Group Plc purchased a new position in Jade Biosciences in the second quarter worth $29,000. Russell Investments Group Ltd. bought a new stake in Jade Biosciences in the second quarter valued at $31,000. BNP Paribas Financial Markets purchased a new position in shares of Jade Biosciences during the 2nd quarter worth approximately $32,000. California State Teachers Retirement System grew its position in shares of Jade Biosciences by 40.3% in the 4th quarter. California State Teachers Retirement System now owns 2,850 shares of the company’s stock worth $44,000 after buying an additional 819 shares during the period. Finally, Group One Trading LLC grew its stake in shares of Jade Biosciences by 122.9% in the 4th quarter. Group One Trading LLC now owns 4,195 shares of the company’s stock worth $65,000 after buying an additional 22,527 shares during the last quarter.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.